News

ScienceAlert on MSN20h
Parkinson's Discovery Suggests We Could Have an FDA-Approved Treatment Already
Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...
Parkinson’s Disease: What We Know and Where Treatment Is Headed
Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...
Are Stem Cell Therapies Safe to Try?
Only a handful of stem cell therapies are currently approved by the F.D.A., mainly for treating blood cancer and immune ...
Rolling Out6d
Parkinson’s disease actually begins in your gut first
Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...
CRISPR helps scientists identify key genes in the development of Parkinson’s disease
For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...
The Lancet19h
CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies
Severe autoimmune-mediated neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and ...
PMLive1d
Roche to advance Parkinson’s disease candidate into phase 3 development
Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety Demonstrated greater α-synuclein ...